Wednesday, July 8, 2026

Patent intelligence · US

US 9701963

Complement component C5 iRNA compositions and methods of use thereof

granted A61KA61K31/713A61K39/3955A61P
Status granted
Linked drugs 3
Pipeline programs 6
Years to expiry 11
Applicant portfolio 379
Patent details — US 9701963
Jurisdiction
US
Status
granted
Grant date
Jul 11, 2017
Expiration
Jul 6, 2037
Claims
32
CPC classes
A61K, A61K31/713, A61K39/3955, A61P
View on Google Patents ↗

Quick answer

US 9701963 (Complement component C5 iRNA compositions and methods of use thereof) is held by Alnylam Pharmaceuticals, Inc.. Status: granted. Granted Jul 11, 2017. Expires Jul 6, 2037 (11 years remaining) — relevant for patent-cliff and LOE planning.

Key facts

Grant date
Expiration
Claims
32
CPC classes
A61K, A61K31/713, A61K39/3955, A61P, A61P1/04, A61P11/06

More from Alnylam Pharmaceuticals, Inc.

Related pharmaceutical patents in our USPTO index.

  1. US 12416006

    Cell death-inducing DFFA-like effector B (CIDEB) iRNA compositions and methods of use thereof

    Alnylam Pharmaceuticals, Inc. · Expires Sep 11, 2045

    granted
  2. US 12404508

    Ketohexokinase (KHK) iRNA compositions and methods of use thereof

    Alnylam Pharmaceuticals, Inc. · Expires Aug 28, 2045

    granted
  3. US 12397013

    Extrahepatic delivery

    Alnylam Pharmaceuticals, Inc. · Expires Aug 21, 2045

    granted
  4. US 12385043

    Modified double-stranded RNA agents

    Alnylam Pharmaceuticals, Inc. · Expires Aug 7, 2045

    granted
  5. US 12385044

    Modified double-stranded RNA agents

    Alnylam Pharmaceuticals, Inc. · Expires Aug 7, 2045

    granted
  6. US 12378553

    Modified double-stranded RNA agents

    Alnylam Pharmaceuticals, Inc. · Expires Jul 31, 2045

    granted
  7. US 12364762

    Biodegradable lipids for the delivery of active agents

    Alnylam Pharmaceuticals, Inc. · Expires Jul 17, 2045

    granted
  8. US 12350338

    Biodegradable lipids for the delivery of active agents

    Alnylam Pharmaceuticals, Inc. · Expires Jul 3, 2045

    granted

Frequently asked questions

What is US patent 9701963?

US 9701963 (Complement component C5 iRNA compositions and methods of use thereof) is held by Alnylam Pharmaceuticals, Inc.. Status: granted. Granted Jul 11, 2017. Expires Jul 6, 2037 (11 years remaining) — relevant for patent-cliff and LOE planning.

Who owns US 9701963?

Alnylam Pharmaceuticals, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 379 pharmaceutical patents for this assignee.

When does US 9701963 expire?

Our index shows an expiration date of Jul 6, 2037 (11 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.